ArticleCancer immunology, immunotherapy : CII2026

GLP-1 receptor agonists at immune checkpoint inhibitor initiation with immune-related and supportive-care outcomes in patients with cancer and overweight or obesity without diabetes: a target trial emulation.

Yu-Jung Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.